Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-11
2009-06-23
Oh, Taylor Victor (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S351000, C514S613000, C546S334000, C564S155000
Reexamination Certificate
active
07550490
ABSTRACT:
The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis.
REFERENCES:
patent: 5958792 (1999-09-01), Desai et al.
patent: 2002/0103192 (2002-08-01), Curtin et al.
patent: 2002/0115716 (2002-08-01), Chaturvedi et al.
patent: 0847992 (1997-09-01), None
patent: 1170008 (2000-07-01), None
patent: WO/0056153 (2000-09-01), None
patent: WO/0118171 (2001-03-01), None
patent: WO/0170675 (2001-09-01), None
patent: WO/0226696 (2002-04-01), None
Ricky W. Johnstone, “Histone deacetylase inhibitors: novel drugs for the treatment of cancer,” Nature Reviews Drug Discovery 2002, 1: 287-299.
Paul A Marks, et al, “Histone deacetylase inhibitors as new cancer drugs,” review Current Opinion in Oncology 2001, 13: 477-483.
Min-Hao Kuo, et al., “Roles of histone acetyltransferases and deacetylases in gene regulation,” BioEssays 20: 615-626 (1998).
Korzus, E., et al., “Transcription Factor-Specific Requirements for Coactivators and Their Acetyltransferase Functions,” www.sciencemag.org. Science, vol. 279, Jan. 30, 1998, 703-707.
Neil J. McKenna, et al., “Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators,” Cell, vol. 106, 465-474 (2002).
Michael J. Pazin, et al., “What's Up and Down with Histone Deacetylation and Transcription?” cell, vol. 89, May 2, 1997, 325-326.
Haihong Zhong, et al., Phosphoryltion of NF-kB p65 by PKA stimulates Transcriptional Acstivity by Promoting a Novel Bivalent Interaction with the Coactivator CBP/p300. Molecular Cell. vol. 1. Apr. 1998. 661-671.
J. S. Staffan, et al., Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration inDrosophila, Nature 2001, 413: 691-694.
Tony Kouzarides, “Histone acetylases and deacetylases in cell proliferation,” Review, Current Opinion Genet. Development 1999, 9: 40-48.
Sandra Jacobson, et al., “Modifying chromatin and concepts of cancer,” Current Opinion in Genetics & Development, 1999, 9: 175-184.
Richard J. Lin, et al., “Transcriptional regulation in acute promyelocytic leukemia,” Oncogene, 2001, 20: 7204-7215.
W. Gu & Robert G. Roeder, “Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain,” Cell, vol. 90, 595-606, Aug. 22, 1997.
Li-Jung Juan, et al., “Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation,” The Journal of Biological Chemistry, vo. 275, No. 27, Jul. 7, 2000, pp. 20438-20443.
Abraham Nudelman, et al., Novel Mutual Prodrug of Retinoic and Butyric Acids with Enhanced Anticancer Activity, Journal of Medical Chemistry, 2000, 43(15), 2962-2966.
Raymond P. Warrell, Jr., et al., “Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemnia by Use of an Inhibitor of Histone Deacetylase,” Journal of the National Cancer Institute, vol. 90, No. 21, Nov. 4, 1998, pp. 1621-1625.
Christopher J. Phiel, et al., “Histone Deacetylase is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen,” The Journal of Biological Chemistry, vol. 276, No. 39, Sep. 28, 2001, pp. 36734-36741.
Akiko Saito, et al., “A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors,” Proc. Natl. Acad. Sci. USA, vo. 96, pp. 4592-4597, Apr. 1999.
E.B. Levit., “Clinical Trials in Leukemia focus on New Treatment Approaches,” 2001 Release—Univ. of Maryland Medical News 2001. Maryland, http://www.umm.edu
ews/releases/karp.html, A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas. 2001. National Cancer Institure.
Deng Tuo
Hu Weiming
Li Boyu
Li Zhi-bin
Lu Xian-Ping
Foley & Lardner LLP
Oh Taylor Victor
Reiter Stephen E.
Shenzhen Chipscreen Biosciences Ltd.
LandOfFree
Benzamide derivatives as histone deacetylase inhibitors with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzamide derivatives as histone deacetylase inhibitors with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamide derivatives as histone deacetylase inhibitors with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4071925